See the details on a bustling stock that's...

 ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

$7.7 BILLION on One Drug? (Insane!) By Andy Snyder, Founder   Click here to see the details on a bustling stock that's... Licensed financial analyst Marc Lichtenfeld breaks down this pandemic-fighter's stock here. "Leading the race to the coronavirus cure," according to CNBC... "[Been] upgraded on high hopes for [coronavirus cure] revenue," according to MarketWatch... And "should be the cornerstone of your portfolio," according to award-winning financial author Marc Lichtenfeld, seen here. Be well, Andy P.S. Analysts at SVB Leerink, who just upgraded the stock to "Outperform" in June, say this company could "generate annual peak revenue of $7.7 billion in 2022" from its coronavirus-fighting drug. Let me repeat that: $7.7 BILLION. In a single year from one drug. Get the urgent details here.     You are receiving this email because you subscribed to Manward Digest. To unsubscribe from Manward Digest, click here. Need help with your account? Click here. Have a question or comment for the editor? Click here. Please do not reply to this email as it goes to an unmonitored inbox. To cancel by mail or for any other subscription issues, write us at: Manward Press | Attn: Support Team | 14 West Mount Vernon Place | Baltimore, MD 21201 North America: 1.800.682.5210 | International: +1.443.353.4263 Website: manwardpress.com Keep the emails you value from falling into your spam folder. Whitelist Manward Digest. © 2020 Manward Press | All Rights Reserved Manward Press is a financial and lifestyle publisher that does not offer any personal financial advice or advocate the purchase or sale of any security or investment for any specific individual. Members should be aware that investment markets have inherent risks and there can be no guarantee of future profits. We expressly forbid our writers from having a financial interest in their own securities recommendations to readers. All of our employees and agents must wait 24 hours after online publication or 72 hours after the mailing of printed-only publications prior to following an initial recommendation. Any investments recommended by Manward Press should be made only after consulting with your investment advisor and only after reviewing the prospectus or financial statements of the company. Protected by copyright laws of the United States and international treaties. The information found on this website may only be used pursuant to the membership or subscription agreement and any reproduction, copying or redistribution (electronic or otherwise, including on the world wide web), in whole or in part, is strictly prohibited without the express written permission of Manward Press, 14 West Mount Vernon Place, Baltimore, MD 21201.